Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (141-150 of 283) with videos related to

Pageof 29
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 4, 2015
Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia PatientsKhoan Vu, Shivaprasad Manjappa, John F DiPersio, et al.
Journal of Clinical Pharmacology|December 8, 2016
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple MyelomaYing Ou, Sameer Doshi, Anh Nguyen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2016
Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well ToleratedRamzi Abboud, Jesse Keller, Michael Slade, et al.
Nature Cancer|August 26, 2024
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trialShambavi Richard, Alexander M Lesokhin, Barry Paul, et al.
Blood|February 21, 2008
Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging studyDrew J Winston, Jo-Anne H Young, Vinod Pullarkat, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 24, 2011
Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantationJacob P Smeltzer, Amanda F Cashen, Qin Zhang, et al.
Blood|October 20, 2020
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myelomaMeletios Dimopoulos, Sara Bringhen, Pekka Anttila, et al.
Blood|February 7, 2012
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemiaGeoffrey L Uy, Michael P Rettig, Ibraheem H Motabi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2008
Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantationIskra Pusic, Shi Yuan Jiang, Scott Landua, et al.
Haematologica|November 23, 2019
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemiaRamzi Abboud, Ezhilarasi Chendamarai, Michael P Rettig, et al.
Pageof 29

Showing results (141-150 of 283) with videos related to

Sort By:
Pageof 29
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 4, 2015
Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia PatientsKhoan Vu, Shivaprasad Manjappa, John F DiPersio, et al.
Journal of Clinical Pharmacology|December 8, 2016
Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple MyelomaYing Ou, Sameer Doshi, Anh Nguyen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2016
Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well ToleratedRamzi Abboud, Jesse Keller, Michael Slade, et al.
Nature Cancer|August 26, 2024
Clinical response and pathway-specific correlates following TIGIT-LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trialShambavi Richard, Alexander M Lesokhin, Barry Paul, et al.
Blood|February 21, 2008
Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging studyDrew J Winston, Jo-Anne H Young, Vinod Pullarkat, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 24, 2011
Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantationJacob P Smeltzer, Amanda F Cashen, Qin Zhang, et al.
Blood|October 20, 2020
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myelomaMeletios Dimopoulos, Sara Bringhen, Pekka Anttila, et al.
Blood|February 7, 2012
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemiaGeoffrey L Uy, Michael P Rettig, Ibraheem H Motabi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 30, 2008
Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantationIskra Pusic, Shi Yuan Jiang, Scott Landua, et al.
Haematologica|November 23, 2019
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemiaRamzi Abboud, Ezhilarasi Chendamarai, Michael P Rettig, et al.
Pageof 29